Cargando…
Atypical hemolytic uremic syndrome in children: complement mutations and clinical characteristics
BACKGROUND: Mutations in complement factor H (CFH), factor I (CFI), factor B (CFB), thrombomodulin (THBD), C3 and membrane cofactor protein (MCP), and autoantibodies against factor H (αFH) with or without a homozygous deletion in CFH-related protein 1 and 3 (∆CFHR1/3) predispose development of atypi...
Autores principales: | Geerdink, Lianne M., Westra, Dineke, van Wijk, Joanna A. E., Dorresteijn, Eiske M., Lilien, Marc R., Davin, Jean-Claude, Kömhoff, Martin, Van Hoeck, Koen, van der Vlugt, Amerins, van den Heuvel, Lambertus P., van de Kar, Nicole C. A. J. |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Springer-Verlag
2012
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3382652/ https://www.ncbi.nlm.nih.gov/pubmed/22410797 http://dx.doi.org/10.1007/s00467-012-2131-y |
Ejemplares similares
-
Serological and genetic complement alterations in infection-induced and complement-mediated hemolytic uremic syndrome
por: Westra, Dineke, et al.
Publicado: (2016) -
ATYPICAL HEMOLYTIC UREMIC SYNDROME AND GENETIC ABERRATIONS IN THE COMPLEMENT FACTOR H RELATED 5 GENE
por: Westra, Dineke, et al.
Publicado: (2012) -
Eculizumab as rescue therapy for atypical hemolytic uremic syndrome with normal platelet count
por: Dorresteijn, Eiske M., et al.
Publicado: (2012) -
The genetics of atypical hemolytic uremic syndrome
por: Feitz, Wouter J. C., et al.
Publicado: (2018) -
Early Eculizumab Withdrawal in Patients With Atypical Hemolytic Uremic Syndrome in Native Kidneys Is Safe and Cost-Effective: Results of the CUREiHUS Study
por: Bouwmeester, Romy N., et al.
Publicado: (2022)